More than 30 years ago, Bispecific T-cell Engager (BiTE®) technology was developed with the goal of finding new ways to help people facing the toughest-to-treat cancers. These efforts came to fruition nearly a decade ago, when Amgen's novel immunotherapy became the first globally approved BiTE® molecule, expanding options for people with advanced B-cell lineage acute lymphoblastic leukemia (B-ALL), a patient population with historically dismal outcomes and limited treatment options. Over the past ten years, it’s been inspiring to see our T-cell engager impact relapsed or refractory and measurable residual disease (MRD)-positive B-ALL patients. Now with @FDA approval for Ph-negative B-ALL patients regardless of their MRD status, Amgen is again poised to transform possibilities for people with this aggressive blood cancer. Read more👇#MyCompany
Today, the U.S. FDA granted approval for Amgen’s Bispecific T-cell Engager (BiTE®) immunotherapy in patients with CD19-positive Ph-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase. 🔗 Press release: https://amgen.ly/3VHKOKX
Vijay Upreti
4mo
Congratulations Amgen!
Senior Vice President, Clinical Solutions and Strategic Partnerships at WCG Clinical
4moExciting to see these exciting new therapies complete clinical trials and become more widely available. Congratulations to the Amgen Team!